Covid Vaccine: Pfizer's success promising for three other efforts, rally may have only just begun

  • Scientific outlet Stat explains that Pfizer's vaccine success is promising for three other efforts. 
  • Approval of other vaccines would hasten the distribution of immunization.
  • The stock market rally may have considerable room to run. 

A COVID-19 vaccine is at hand – the earth-shattering news from Pfizer and BioNTech has sent markets surging. Immunization efforts have been in the works for many months and the world was hopeful for a breakthrough before the end of the year. Nevertheless, the announcement is a massive development. 

The pharma firms say that the vaccine is 90% effective in preventing infections and has no safety issues after conducting a 43,500-strong Phase 3 trial. Pfizer has not been waiting for the results to begin producing doses, with some countries are already pre-ordering them. However, production bottlenecks and freezing storage temperatures may have 

Investors may ask themselves – is everything already priced in? Probably not. 

Scientific publication STAT has provided details on the groundbreaking development which consists of a critical factor. They say that the efforts by AstraZeneca, Modena Johnson use a similar approach – a pre-fusion spike as their immunogen – which means a high probability of success for their efforts as well

Here is a tweet by Helen Branswell, senior writer and expert on infectious diseases with Stat: 

If all four covid vaccines receive emergency approvals, they could all begin distributing their solutions to the world rapidly. Shortening the time-to-market would allow economies a quicker return to the old, pre-pandemic, normal

For investors, that means the market rally has more room to run with every such approval. Pfizer is the winner in the race, but the others may be winners as well – and so could humanity and stock bulls. 

Update: Dr. Anthony Fauci, the NIH Director, has said that Moderna's vaccine may yield similar results to that of Pfizer. 

More Pfizer jumps after covid vaccine news, but is vulnerable to competition

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.

Analysis feed

FXStreet Trading Signals now available!

Access to real-time signals, community and guidance now!

Latest Analysis

Latest Forex Analysis

Editors’ Picks

AUD/USD fades an uptick above 0.7400 despite upbeat China's PMIs

AUD/USD pares gains and drops back below 0.7400 amid a cautious market mood, reflected by the losses in the S&P 500 futures. Australian-Sino trade tussle outweighs the vaccine optimism and upbeat Chinese NBS PMIs. 


EUR/USD: Refreshes three-month high towards 1.2000, battles triangle resistance

EUR/USD eases from fresh high since September 01. The pair rose to the highest in three months before a few hours but couldn’t cross the upper line of a five-week-old ascending triangle formation. RSI conditions warrant caution, bears are less likely to take entries above 1.1870.


NZD/USD refreshes 2.5-year high on strong China PMI above 0.7400

NZD/USD rises to the fresh high since June 2018 after China data. China’s NBS Manufacturing PMI, Non-Manufacturing PMI beat market forecasts in November. ANZ Business Confidence, Activity Outlook also came in positive for November.


Gold: Trades below 200-day MA for first since March

Gold is trading below the widely-followed 200-day Simple Moving Average (SMA) for the first time since March. The metal is changing hands near $1,783 per ounce, representing a 0.25% loss on the day. 

Gold news

Black Friday 2020 Discounts!

Learn to trade with the best! Don't miss the most experienced traders and speakers in FXStreet Premium webinars. Also if you are a Premium member you can get real-time FXS Signals and receive daily market analysis with the best forex insights!

More info

Forex Majors